Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Endpoint
Sort By
Newest First
Sign in
1 / 1
1 / 1
Endpoints
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, Has Been Met, Confirming Previously Published Activity
MorphoSys
PR-M05-19-NI-065
May 22, 2019
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Eli Lilly and Company
PR-M03-19-NI-039
Mar 14, 2019
